Retatrutide
Triple GIP/GLP-1/glucagon agonist
Research overview
A triple-acting peptide on the GIP, GLP-1 and glucagon receptors, with one of the largest weight reductions reported for a single research agent.
Descriptions reference published research areas for laboratory context only and are not claims of efficacy, safety, or intended use in humans or animals.
- Price
- $450 CAD
- Purity
- ≥99% (HPLC)
- Presentation
- 10 mg lyophilized vial
Order / inquire about Retatrutide
Email our research desk for availability, batch Certificates of Analysis, and account setup. We respond to verified research inquiries from Canada only.
Verified Canadian research inquiries only · 18+
For laboratory research use only — not for human or veterinary use
Retatrutide is a chemical reference material sold strictly for in-vitro laboratory research by qualified professionals. It is not a drug, food, cosmetic, or natural health product; it has not been evaluated or approved by Health Canada; and it must never be ingested, injected, or applied to humans or animals. Sold in Canada only, to purchasers 18+. See our Research Use Policy.
Research encyclopedia
Everything the literature has studied.
For laboratory research use only — not for human or veterinary use. The content below summarizes published research context only. It is not medical advice, makes no therapeutic claims, and describes no intended use in humans or animals. These materials have not been evaluated or approved by Health Canada.
What it is
Synthetic triple agonist of the GIP, GLP-1, and glucagon receptors, investigated for weight and metabolic control. It reported one of the largest single-agent weight reductions in a phase 2 trial; still investigational (phase 3 as of 2026).
Mechanism of action
Simultaneously activates three receptors: GLP-1 and GIP reduce appetite and slow gastric emptying, while the glucagon component increases energy expenditure and mobilizes hepatic fat. This triple action underlies the magnitude of the metabolic response observed, and the glucagon arm can transiently raise heart rate and glucose.
Research areas
- Obesity and weight-management research (phase 2, TRIUMPH)
- Glycemic control in type 2 diabetes
- Hepatic steatosis (MASLD/NAFLD)
- Metabolic and lipid parameters
Studied effects in research models
- ~24% mean weight reduction at 48 weeks in phase 2 (highest doses)
- Improvements in HbA1c and glucose
- Marked reduction in liver fat
Effects listed describe observations reported in laboratory or animal research models only — not outcomes claimed for humans or animals.
Biomarkers tracked in related research
Discovery & background
Developed by Eli Lilly (LY3437943), extending the tirzepatide lineage by adding glucagon-receptor agonism to raise energy expenditure and mobilize hepatic fat. Its phase 2 obesity trial, published in NEJM in 2023 (Jastreboff et al.), reported striking weight reductions; phase 3 (TRIUMPH program) is ongoing.
Considerations & limitations
Research use only. Investigational — not approved by Health Canada, the FDA, or other regulators; phase 3 trials ongoing, so long-term safety and cardiovascular outcomes are not established. Evidence is largely preliminary (mainly NEJM 2023 phase 2). Class warning for medullary thyroid carcinoma/MEN2, pancreatitis, and gallbladder disease; the glucagon component may raise heart rate; excluded in pregnancy/lactation. As a recent molecule, identity verification is especially important — require COA with HPLC/MS, net peptide content, sequence identity, and endotoxin testing.
References
- [1]Jastreboff et al., 2023 (retatrutide phase 2, obesity) — N Engl J Med; PMID: 37366315
- [2]Rosenstock et al., 2023 (retatrutide phase 2, type 2 diabetes) — Lancet; PMID: 37356446
- [3]Coskun et al., 2022 (LY3437943 discovery/pharmacology) — Cell Metab; PMID: 36228616
- [4]Sanyal et al., 2024 (retatrutide and liver fat/MASLD) — Nat Med; DOI: 10.1038/s41591-024-03018-2